Eradication of poliomyelitis will not be easy. Vaccines and vaccine manufacture are part of the solution but part of the problem too.
Eradication of polio

For:
1. two good vaccines
2. no animal reservoir

Against:
1. silent infections
2. vaccine issues
3. tropical countries
4. money, management, logistics, politics, sociology
5. What is eradication?
Progress 1988-2000

1988
350,000 cases

1988
>99% decline in cases

2000
2,797 cases
Wild Poliovirus*, 15 Apr 2002 to 14 Apr 2003

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO 2003. All rights reserved

*Excludes viruses detected from environmental surveillance and vaccine derived polio viruses.

Data in WHO HQ as of 15 April 2003.
Wild Poliovirus*, 13 Jul 2004 to 12 Jul 2005

*Excludes viruses detected from environmental surveillance and vaccine derived polio viruses.

Data in WHO HQ as of 12 Jul 2005
If one country has polio the world is at risk.
cVDPVs: circulating vaccine derived poliovirus strains which cause outbreaks

Arise where vaccine coverage is poor or patchy.

Outbreaks in Hispaniola, Egypt, Madagascar, Phillipines, China, Nigeria, etc
Relationship Between Sabin 1-Derived Isolates from Haiti and the Dominican Republic to Type 1 Wild Polioviruses

VP1 (906 nt)
The Gravity of the Problem in Nigeria: type 2 circulating Vaccine-derived Poliovirus (cVDPV)

Rolling 6 months map: 5 Dec 2007 – 4 Jun 2008

- cVDPV (28 cases)

dots are randomly placed within districts

Data in WHO HQ as of 04 Jun 2008
Hypogammaglobulinaemic patients can become chronic excreters of poliovirus after receiving OPV by mistake. The world record so far is over twenty five years.
Live oral polio vaccine can revert to circulating paralytic poliovirus. Prolonged excretion of poliovirus is possible.
Solution to the OPV issue

Stop using OPV to prevent new VDPVs.
Immunise with IPV to maintain protection.
# IPV usage according to GPEI

<table>
<thead>
<tr>
<th>Category of countries</th>
<th>Birth (Million, 2015)</th>
<th>Demand (Million, 2017)</th>
<th>Major countries</th>
<th>Potential IPV adoption scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current users&lt;sup&gt;1)&lt;/sup&gt;</td>
<td>20.0</td>
<td>74</td>
<td>• U.S., Mexico, Russia and others</td>
<td>n/a</td>
</tr>
<tr>
<td>High income countries</td>
<td>0.1</td>
<td>0.3</td>
<td>• Singapore, Equatorial Guinea and others</td>
<td>2011</td>
</tr>
<tr>
<td>Self-producers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eradication independent</td>
<td>19.6</td>
<td>70</td>
<td>• China, Japan</td>
<td>2013</td>
</tr>
<tr>
<td>Eradication dependent</td>
<td>32.5</td>
<td>89</td>
<td>• India/Indonesia, Brazil</td>
<td>2015 or later</td>
</tr>
<tr>
<td>Upper middle-income countries&lt;sup&gt;2)&lt;/sup&gt;</td>
<td>2.1</td>
<td>6</td>
<td>• Algeria, Malaysia, Kazakhstan, Libya and Serbia&lt;sup&gt;3)&lt;/sup&gt;</td>
<td>2013</td>
</tr>
<tr>
<td>Eradication independent</td>
<td></td>
<td></td>
<td>• China</td>
<td></td>
</tr>
<tr>
<td>Eradication dependent</td>
<td>2.9</td>
<td>8</td>
<td>• Colombia, Argentina, Venezuela&lt;sup&gt;4)&lt;/sup&gt;</td>
<td>2015 or later</td>
</tr>
<tr>
<td>Lower middle-income countries&lt;sup&gt;2)&lt;/sup&gt;</td>
<td>6.7</td>
<td>22</td>
<td>• Egypt, Iran, Iraq, Thai, Guatemala&lt;sup&gt;5)&lt;/sup&gt;</td>
<td>2017</td>
</tr>
<tr>
<td>2-4-6 month schedule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-10-14 wk schedule</td>
<td>3.0</td>
<td>10</td>
<td>• Philippine, Morocco, Cape Verde and others</td>
<td>2017</td>
</tr>
<tr>
<td>GAVI countries</td>
<td>50.3</td>
<td>96</td>
<td>• Nigeria, Pakistan, Bangladesh, Ethiopia, DR Congo&lt;sup&gt;6)&lt;/sup&gt;</td>
<td>2017 or later</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>137.3</strong></td>
<td><strong>375</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

1) Include both standalone and Combo IPV use. Assumes non-Hexa IPV users will shift to Hexa in 2011
2) Excluding GAVI countries
3) Top 5 countries representing 87% of birth cohort
4) Top 3 countries representing 75% of birth cohort
5) Top 5 countries representing 87% of birth cohort
6) Top 5 representing 43% and top 10 (plus Tanzania, Uganda, Kenya, Serbia, Afghanistan, Vietnam) represent 61% of birth cohort
7) Representing tentative use in post-eradication
IPV manufacture

Grow wild type virus
Treat with diluted formalin for twelve days
Use
The Cutter Incident (1955)

Poliomyelitis in 60 recipients and 89 contacts of vaccine.

Live virus isolated from vaccine. Occurred within seven days of the licence being granted.

Founding of the Biologicals arm of FDA as we know it.
IPV production systems are the biggest single concentration of poliovirus on the planet. Escapes have been documented in the past. Although facilities have improved the entry of new manufacturers is possible. This may be the most likely source of polio re-emergence if the wild type is truly eradicated.

At the moment there are four manufacturers of licensed IPV, all in Europe.
Reasons to use the Sabin strains

1. Safer than wild type
2. Provide a base for restarting OPV production in an emergency.
Strains used for preparation of Inactivated Polio Vaccine

<table>
<thead>
<tr>
<th>Serotype</th>
<th>Strain Source</th>
<th>Year</th>
<th>Origin</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mahoney Stool</td>
<td>1941</td>
<td>USA</td>
<td>Healthy</td>
</tr>
<tr>
<td>2</td>
<td>MEF-1 CNS</td>
<td>1942</td>
<td>Middle East</td>
<td>Paralytic</td>
</tr>
<tr>
<td>3</td>
<td>Saukett Stool</td>
<td>1950</td>
<td>USA</td>
<td>Paralytic</td>
</tr>
</tbody>
</table>

61st World Health Assembly resolution on longterm poliovirus risk management

Implications for GAPIII:

- Formally acknowledges goal of safer and more affordable IPV production
- Safeguards revised and re-organized
- Timing of safeguard implementation adjusted
Some issues

1. Assays.
2. Efficacy.
3. Yields and production.
5. Combination vaccines and interactions.
6. CONTAINMENT.
Developing country production

Interest by a number of vaccine manufacturers in the developing world to produce sIPV.
Large countries seem to be especially interested in producing sIPV, including China, India and others.
To produce sIPV safely, prospective manufacturer needs to make substantial capital and human resource investments to meet not only the GMP but also the containment requirements for sIPV.
Production in developing countries could lead to substantial reductions in cost of sIPV production.

WHO/UNICEF Consultation meeting 2007
Prequalification (WHO)

Six functions of the National Regulatory Authority:

- Licensing
- Surveillance of vaccine performance
- Lot release
- Lab access
- GMP inspections
- Clinical evaluation
Design of mutilated strains
Summary

Polio is very nearly eradicated. Vaccination will continue for some time, particularly with IPV. It is unlikely that production will be confined to the existing manufacturers. This has pluses and minuses which might be addressable.